Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 70, 88-100

Beneficial Effects of Dual TORC1/2 Inhibition on Chronic Experimental Colitis


Beneficial Effects of Dual TORC1/2 Inhibition on Chronic Experimental Colitis

Shurong Hu et al. Int Immunopharmacol.


Background and aim: AZD8055, a new immunosuppressive reagent, a dual TORC1/2 inhibitor, had been used successfully in animal models for heart transplantation. The aim of this study was to evaluate the effects and mechanisms of AZD8055 on chronic intestinal inflammation.

Methods: Dextran sulfate sodium (DSS) - induced chronic colitis was used to investigate the effects of AZD8055 on the development of colitis. Colitis activity was monitored by body weight assessment, colon length, histology and cytokine profile analysis.

Results: AZD8055 treatment significantly alleviated the severity of colitis, as assessed by colonic length and colonic damage. In addition, AZD8055 treatment decreased the colonic CD4+ T cell numbers and reduced both Th1 and Th17 cell activation and cytokine production. The percentages of Treg cells in the colon were also expanded by AZD8055 treatment. Furthermore, AZD8055 effectively inhibited mTOR downstream proteins and signal transducer and activator of transcription related proteins in CD4+ T cells of intestinal lamina propria.

Conclusions: These findings increased our understanding of DSS-induced colitis and shed new lights on mechanisms of digestive tract chronic inflammation. Dual TORC1/2 inhibition showed potent anti-inflammatory and immune regulation effects by targeting critical signaling pathways. The results supported the strategy of using dual mTOR inhibitor to treat inflammatory bowel disease.

Keywords: AZD8055; Chronic colitis; Inflammatory bowel disease; JAK/STAT; mTOR.

Similar articles

See all similar articles

MeSH terms